Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...

Merck KGaA (OTCMKTS:MKGAF – Get Free Report)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $147.57 and traded as low as ...

This report covers recent health news, including Robert F. Kennedy Jr.'s legal fees from Merck litigations, rejections of a ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

(Legal Fee Tracker is a weekly feature focused on attorney compensation. Please send tips or suggestions to ...

The increasing demand for biopharmaceuticals is a significant driver of the Global Bioanalytical Services market Industry US, NY, UNITED STATES, January 22, 2025 /EINPresswire / -- Global ...